Quarterly Report
Brisbane, Jan 30, 2019 AEST (ABN Newswire) - Anatara Lifesciences Ltd (
ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st December 2018. The Company's cash position at the end of the quarter stood at $1.5m. The Company also had $4,500,000 in deposits with terms of greater than 90 days. Expenditure during the quarter was in line with forecast.
On 14th January 2019, the Company received $1,249,299 from the Australian Taxation Office under the Federal Government's Research and Development (R&D) Tax Incentive scheme.
The Company announced on 29th October 2018, it had received approval from the Australian Pesticides and Veterinary Medicines Authority (APVMA) for its animal health product licensed to Zoetis Inc. The animal health product Detach has the approved label, "To aid in the control of scour and has positive health benefits in weaned piglets from 3 weeks of age and help increase survivability of scouring pre-weaning piglets".
Anatara was also delighted to announce the appointment of Mr Steven Lydeamore as Chief Executive Officer (CEO) on 14th November. Mr Lydeamore has 26 years' international experience in the pharmaceutical industry, working in Australia, USA and Canada. He brings a strong track record of successfully commercialising products on a global scale, thereby driving sales growth and shareholder value.
The Company's Product Development Advisory Board, comprising prominent independent experts in human gastrointestinal health to assist the Company in developing our first human health product, held its inaugural meeting. The Company's product candidate known as the Gastrointestinal ReProgramming (GaRP) dietary supplement, an evidence-based product aimed at restoring and maintaining gut health, is well advanced in proof of concept studies.
Looking ahead to 2019, Anatara remains focused on its new business strategy in human health, and in particular the development and partnering of its GaRP dietary supplement. With foundations built on strong and successful science, GaRP has been designed to address the primary underlying factors associated with gastrointestinal disorders such as Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD).
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
| ||
|
